Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The right drugs developed at the right time improve patients’ lives, but it takes dedication. The process can be long and complex, taking place in an ever-changing, intensely competitive environment. As the trusted pharma research partner for the top 50 global pharmaceutical companies, we come alongside your team to provide reliable, timely intelligence and insights.
How we help
Whether planning, developing, or launching, we can help you:
By Ian Schofield 29 Nov 2022
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
25 Nov 2022
Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
By David Wallace 25 Oct 2022
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Topic Company Analysis
By Jung Won Shin 25 Oct 2022
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Topic Company Analysis Strategy
20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
06 Oct 2022
Takes a deep dive into the clinical trial landscape in the Asia-Pacific (APAC) region over the past decade, from 2012 to 2021. APAC has become a hotspot for clinical trials, with trial activity trending upwards and eventually contributing almost half of the entire global clinical trial activity in 2021
23 May 2022
In this report, we cover catalysts from 31 drugs, devices, diagnostics, and deals expected to occur in the second quarter of 2022.
08 Feb 2022
In pharma’s fast paced and continually evolving world, accurately anticipating the impact of events on the horizon is critical to your success.
Topic Business Strategies
02 Feb 2022
To highlight the growing importance of IO and especially IO combination trials within oncology clinical development, visual trends and key insights about the past 20+ years were compiled.
By Chloe Kent 18 Jan 2022
Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.
By David Wallace 18 Jan 2022
WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.
By Scrip Team 18 Jan 2022
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.